Results 21 to 30 of about 3,580,419 (303)

Biopsy confirmation of metastatic sites in breast cancer patients:clinical impact and future perspectives [PDF]

open access: yes, 2014
Determination of hormone receptor (estrogen receptor and progesterone receptor) and human epidermal growth factor receptor 2 status in the primary tumor is clinically relevant to define breast cancer subtypes, clinical outcome, and the choice of therapy.
Carmen Criscitiello   +38 more
core   +2 more sources

Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab [PDF]

open access: yes, 2005
Background: HER2 is overexpressed in 20 - 30% of breast cancers. Compared to chemotherapy alone, chemotherapy with trastuzumab improves clinical outcome in patients with HER2- positive metastatic breast cancer ( MBC). In general, HER2 status in a primary
Lässig, D.   +3 more
core   +1 more source

The Metabolic Mechanisms of Breast Cancer Metastasis

open access: yesFrontiers in Oncology, 2021
Breast cancer is one of the most common malignancy among women worldwide. Metastasis is mainly responsible for treatment failure and is the cause of most breast cancer deaths.
Lingling Wang   +3 more
doaj   +1 more source

Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer [PDF]

open access: yes, 2007
Background: Patients with metastatic breast cancer (MBC) are increasingly exposed to anthracyclines and taxanes either during treatment of primary breast cancer or during initial therapy of metastatic disease.
Vehling-Kaiser, U.   +13 more
core   +1 more source

Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis

open access: yesBMC Cancer, 2009
Background Bone metastases are frequent complications of breast cancer. Recent literature implicates multiple chemokines in the formation of bone metastases in breast cancer.
Zheng Xin   +6 more
doaj   +1 more source

Role of gemcitabine in the treatment of advanced and metastatic breast cancer [PDF]

open access: yes, 2003
Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second ...
Heinemann, Volker
core   +1 more source

Moonshots and metastatic disease: the need for a multi-faceted approach when studying atypical responses

open access: yesnpj Breast Cancer, 2017
Clinical research generally focuses on results involving a statistical mean with little attention in trial design to patients who respond considerably better or worse than average.
Kristine De La Torre   +4 more
doaj   +1 more source

Prognostic factors in metastatic breast cancer: a prospective single-centre cohort study in a Finnish University Hospital

open access: yesBMJ Open, 2020
Objectives Although novel early breast cancer prognostic factors are being continuously discovered, only rare factors predicting survival in metastatic breast cancer have been validated.
Peeter Karihtala   +3 more
doaj   +1 more source

In silico analysis of differentially expressed genesets in metastatic breast cancer identifies potential prognostic biomarkers

open access: yesWorld Journal of Surgical Oncology, 2021
Background Identification of specific biological functions, pathways, and appropriate prognostic biomarkers is essential to accurately predict the clinical outcomes of and apply efficient treatment for breast cancer patients.
Jongchan Kim
doaj   +1 more source

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer [PDF]

open access: yes, 2013
IntroductionBreast cancer remains a significant scientific, clinical and societal challenge. This gap analysis has reviewed and critically assessed enduring issues and new challenges emerging from recent research, and proposes strategies for translating ...
Gee, Julia M. W.   +645 more
core   +3 more sources

Home - About - Disclaimer - Privacy